What the business is, and whether it's a good one at a fair price.
Runs a national chain of diagnostic laboratories and patient-facing collection touchpoints, offering pathology tests, specialty diagnostics (oncology, neurology, genomics), and wellness/preventive panels. Pathology services accounted for 96.6% of segment revenue, with the residual 3.4% from other income (FY19 segment disclosure). In FY26, the business served 14 million patients and ran 30 million tests across 210+ labs and more than 5,000 service touchpoints spread over 750+ towns in India, with operations in 21 countries. Specialty testing contributed 37% of revenue and TruHealth wellness 19%, while digital channels accounted for 25% of revenue. The Core Diagnostics acquisition was integrated ahead of schedule, reaching high-single-digit EBITDA in Q4 FY26. The company is planning to add 100 mini hubs (pathology plus basic radiology) and 1,500 new collection centres over the next three years. The cost base is dominated by employee costs (22.9% of revenue), other operating expenses (33.0%), and diagnostic materials and consumables (19.7%).
Measured from the filed financials, judged against its Healthcare Service Provider peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from METROPOLIS HEALTHCARE LTD's filed financials and exchange disclosures
METROPOLIS HEALTHCARE LTD is a Healthcare Services company listed on NSE and BSE, trading under the symbol METROPOLIS.
Yes. Over the trailing twelve months METROPOLIS HEALTHCARE LTD reported a net profit of ₹203 Cr on revenue of ₹1,710 Cr.
Yes. The dividend yield is 0.17% at the current price. It paid out 11% of its profit as dividend in FY26.
Effectively yes. It holds ₹36 Cr more cash than debt. Debt stands at 0.01× equity.
On trailing P/E, METROPOLIS HEALTHCARE LTD ranks 16 of 29 in Healthcare Service Provider — cheaper than 46% of them, against an industry median of 23.2×. This is a position, not a valuation judgement.
On a typical session METROPOLIS HEALTHCARE LTD moves 1.11% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by METROPOLIS HEALTHCARE LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
